Another delay for a long awaited drug

July 1, 2014

The introduction of Levadex has been delayed again, this time for a year. It seems like deja vu all over again – I wrote the same thing on this blog in April of last year. Levadex, which the manufacturer (Allergan) just renamed as Semprana, is an inhaler containing DHE. DHE, or dihydroergotamine is one of the most effective injectable drugs for migraine. It should be even better in an inhaled form because it works faster and causes much less nausea than the injection. The FDA is again delaying the launch because of manufacturing problems. Apparently, the particle size of the drug when it comes out of the inhaler is not uniform enough. Many patients are unhappy, but I am sure that the Allergan is very unhappy too since they spent almost a billion dollars to acquire this drug from a small company that developed it.

Written by
Alexander Mauskop, MD
Continue reading
September 7, 2025
How Artificial Sweeteners May Be Affecting Your Brain
A large Brazilian study published in Neurology followed nearly 13,000 adults for eight years and found something troubling: people who consumed the most artificial sweeteners showed faster cognitive...
Read article
August 30, 2025
Lithium Levels are low in Alzheimer’s. Is there a role in Migraine and Chronic Pain?
Recently published research on lithium deficiency in Alzheimer’s disease has caught the attention of the media. As a neurologist specializing in pain and headache medicine with an interest in no...
Read article
August 16, 2025
The Healing Power of Holding Hands: Insights from Neuroscience on Pain Relief
There’s something powerful about human touch when you’re hurting. As a neurologist, I see every day how a gentle hand squeeze from someone you trust can shift your pain—not just emotionally, but in...
Read article